Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 2/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 8/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | ELOVL1 | Q9BW60 | 2/20 | 0.33 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10182056 | 0.84 | MKNK1 (0.36) | GRM4MKNK1GRM5GRM2IRAK4 | |
| SCHEMBL15745931 | 0.82 | CYP11B2 (0.39) | GRM4MKNK1CYP11B2GRM5ELOVL1 | |
| SCHEMBL12410577 | 0.81 | ASIC3 (0.40) | GRM4MKNK1CYP11B2GRM5ELOVL1 | |
| SCHEMBL12410583 | 0.81 | MKNK1 (0.40) | GRM4MKNK1GRM5MKNK2 | |
| SCHEMBL12410479 | 0.80 | SMN1; SMN2 (0.40) | GRM4MKNK1CYP11B2GRM5NPC1 | |
| SCHEMBL12410390 | 0.80 | GRM5 (0.43) | GRM4MKNK1CYP11B2GRM5DYRK1B | |
| SCHEMBL18567909 | 0.79 | IRAK4 (0.41) | GRM4MKNK1ELOVL1NPC1SLC6A9 | |
| SCHEMBL10233513 | 0.79 | GRM2 (0.44) | ELOVL1GRM2IRAK4 | |
| SCHEMBL3395383 | 0.79 | NPC1 (0.35) | GRM4MKNK1CYP11B2GRM5ELOVL1 | |
| SCHEMBL12410580 | 0.79 | GRM5 (0.45) | GRM4MKNK1CYP11B2GRM5ELOVL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585451-B1 | HETEROCYCLIC COMPOUNDS AS AGENTS FOR PEST CONTROL | BAYER IP GMBH (DE) | 2017-03-01 | — | — | EP | disclosed |
| US-20120165345-A1 | Heterocyclic compounds as pesticides | BAYER CROPSCIENCE AG (DE) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165345-A1 | Heterocyclic compounds as pesticides | DDT, ACHE, PTMS | GRM4 892/4885MKNK1 1426/4885CYP11B2 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.